china biopharm partnering forum

English

简体中文

2019 AGENDA

26TH SEP PLENARY SESSION

08:00-08:55 Registration

08:55-09:00 Opening of the BioPharm2019

09:00-09:30 Interpretation of Action Plan for Promoting High Quality Development of Shanghai Biomedical Industry

Shupei DONG, Investigator of Biomedicine Department, Associate Researcher, Shanghai Science and Technology Commission

09:30-10:00 To Be Determined

Hui FENG, Executive Director and COO, Shanghai Junshi Biosciences Co., Ltd.

10:00-10:30 The Medical Platform Immunity Transformation of Assists the R&D of New Tumor Immune Drugs

Qunsheng JI, VP, Head of Oncology & Immunology Unit, WuXi AppTec

10:30-10:40 Talking About Changxing and Winning in the Future – Investment Promotion of Shanghai

Changxing Marine Equipment Industry Park

Cong YU, Chairman, Shanghai Changxing Marine Equipment Industry Park

10:40-11:00 Tea Break & Exhibitions

11:00-12:00 Panel Discussion: Deepen the Drug Examination and Approval System, Speed up R&D and Reduce time-to-market of New Drugs in China

Moderator:

Ye HUA, Founder, Chairman and CEO, BioNova Pharmaceuticals

Panelist:

Haizhou ZHANG, CEO, BJMab Biopharmaceuticals Inc

Jason YANG, Chief Medical Officer and SVP of Clinical Development and Regulatory Affairs ,

Cstone Pharmaceuticals

Janet LYU, Head of Product Development Regulatory China, Roche (China) Ltd.

11:50-12:00 Q&A

26TH SEP PARALLEL SESSION 1：
26TH SEP PARALLEL SESSION 2：

13:30-14:15 Panel Discussion: R&D Difficulties and Market Prospects of Macromolecular Drugs
Moderator:Min DONG, EVP, Global Clinical Development, Clover Biopharmaceuticals
Panelist:
Rong CHEN, Chief Medical Officer, JHL Biotech
Ziping WEI, Chief Executive Officer, Bliss Biopharmaceutical
Bo SHAN, Vice President, Discovery, Early Development and Facility, Antengene Corporation
14:15-14:45 Progress and Risk Control of Tumor Immunotherapy
Jing MA, Researcher, National Shanghai Center for New Drug Safety Evaluation and Research
14:45-15:15 A New Model of Antibody Drug Research and Development: One-stop Research and Development Platform Based on Fully Human Antibody RenMab Mice and in vivo Pharmacodynamics
Yuelei SHEN, Chairman & CEO, BIOCYTOGEN
15:15-15:45 Machine Learning for Drug Discovery and Development
Tao HUANG, Founder & CEO, DeepDrug
15:45-16:05 Tea Break & Exhibitions
16:05-16:35 Integrated High-Flux R&D Service Platform for Innovative Antibody Drugs
Bo JIN, Marketing Director, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd.
16:35-17:05 Starting from China, Globally Oriented: The First Unique Innovation Drug Model
Wen LUO, Chief Executive Officer, Chief Scientific Officer, Denovo Biopharma
17:05-17:35 The Past, Present and Future of ADC Products Development
Youling WU, Chairman and President, Teruisi Pharmaceutical Inc
17:35-18:05 Development and Future Layout of Bispecific Antibodies
Bin PENG, CMO, EpimAb Biotherapeutics

If you are interested to recommend speakers to us,please send us information.And we shall contact you if your recommendation is accepted.

recommend a speaker

27TH SEP PARALLEL SESSION 3：
27TH SEP TAIWAN PARALLEL SESSION：
27TH SEP TAIWAN USA SESSION：

09:00-09:30 Developing Life-changing Drugs for Patients Based on Innovation and Cooperation
Feng BIAN, Senior Director, Asia Emerging Science Lead (Shanghai), Asia Discovery Labs (ADL),
Emerging Science & Innovation (ES&I), Pfizer Worldwide R&D
09:30-10:00 A Preliminary Study on the Current Situation and Strategies of NASH New Drugs
Zhou ZHOU, Director of Pharmacology and Scientific Affairs, Terns China Biotechnology Co., Ltd.
10:00-10:30 The Latest Research Progress and Technical Breakthrough of the New Generation of "Oncolytic
Virus Therapeutics"
Grace ZHOU, Founder and CEO, Immvira
10:30-10:50 Application and Prospect of High-Flux Single Cell Analysis Platform in Innovative Drug R&D
Jeff HE, Co-Founder & COO, HiFIBiO Therapeutics
10:50-11:10 Tea Break & Exhibitions
11:10-11:30 Think Globally in Biotech Patenting and International Biotech Transaction in the Trade-War Era
Alex Y. NIE, Partner, Sheppard Mullin Richter & Hampton
Harris GAO, Partner, Sheppard Mullin Richter & Hampton
11:30-12:00 Transgenic Mouse Platforms Generating Fully Human Monoclonal Antibodies Assist the
Development of Innovative Tumor Immunotherapy
Sixiang ZHOU, Senior Director Asia Pacific, Harbour BioMed
12:00-12:30 The Research Progress and Challenges of Oncolytic Virus
Binlei LIU, Chairman, Wuhan Binhui Biotechnology Co.,Ltd.
12:30-13:30 Lunch
13:30-14:00 Opportunities and Barrier in Cell Therapy Clinical Research
Christy MA, Director, Clinical Development, Lion TCR Pte Ltd.
14:00-14:30 Multidisciplinary Cooperation for Cancer Biomarker Identification and Commercialization
Jay DONG, Global Vice President, President of Asia Pacific Region, General Manager of CST China
14:30-15:00 Biomarker Detection Based on NGS Platform Helps Drug Development Precisely
Di WANG, Product Director of Business Development Center, Genetron Health
15:00-15:20 Lingang Changxing – Creating Value for the Industry
Xin YANG, Leasing Director, Shanghai Lingang Changxing SCI-TECH City
15:20-15:40 Tea Break & Exhibitions
15:40-16:10 Development Status and Future Blueprint of China's Emerging Bio-Innovative Drugs
Lianshan ZHANG, Member of the Board, Senior Vice General Manager, President of Global R&D,Hengrui Medicine
16:10-17:00 Panel Discussion: The Emerging New Methods and Technologies for Drug R&D
Moderator:Jing LI, President, Pharma Codia
Panelist:
Sheng FENG, Senior Director, Data Sciences, Parexel
Tony GUO, Executive Director, Global Head of Biometrics, BeiGene
Bruce XUE, Executive Director, Head of Data Sciences, Shanghai Junshi Biosciences Co., Ltd.
Zhiyang CHEN, Vice President of Customer Service, Asia-Pacific (Excluding Japan ), Medidata